KYV-101, a therapeutic agent by Kyverna, has been granted approval by the American FDA for use in a Phase 2 study, KYSA-7, targeting individuals suffering from advanced, treatment-resistant Multiple Sclerosis.

GPN Vaccines Announces Encouraging Safety and Immunogenic Response Results in Initial Phase Trial of its Gamma-PN Vaccine.

Bayer AG and its independent subsidiary Asklepios BioPharmaceutical, Inc., focused on gene therapy, have completed data collection for the AB-1005 (AAV2-GDNF) Phase Ib trial after 18 months.

Genascence Corporation has launched a Phase 1b clinical study to evaluate the efficacy of their gene treatment, codenamed GNSC-001, targeting knee osteoarthritis.

Upstream Bio has initiated the first patient treatments in a Phase II study on Verekitug (UPB-101) targeting Chronic Rhinosinusitis with Nasal Polyps.

Ventus Therapeutics has begun trials on VENT-03, an oral drug designed to block cGAS, marking a pioneering approach in this category.

Alvotech, a global biopharma company specializing in biosimilars, reported positive early results from a key trial of AVT06, its candidate similar to Eylea® (aflibercept).

OBI Pharma announced the FDA has approved its investigational new drug application for OBI-992, allowing the start of a phase 1/2 clinical trial to evaluate their novel TROP2-targeted antibody-drug conjugate for cancer treatment.

Belief BioMed Group announced the start of patient treatment in a major BBM-H803 study. This gene therapy aims to treat hemophilia A and is independently developed by Belief BioMed.

Sciwind Biosciences Reveals Encouraging Preliminary Outcomes from a Final-Stage Study of Ecnoglutide (XW003), an Extended-Duration GLP-1 Mimetic with Selective cAMP Pathway Activation, in Chinese Adults Suffering from Type 2 Diabetes.

Coherus BioSciences, Inc. has recently declared that their product, LOQTORZI™ (toripalimab-tpzi), can now be acquired from certain specialty distribution channels within the U.S. market.

Atom Bioscience, a biotech company specializing in innovative therapies for inflammation and metabolic diseases, announced FDA approval for the Phase 1 trial of its new drug, ABP-745.